Sandoz, a Novartis division, announced that the U.S. Food and Drug Administration approved a citrate-free high-concentration formulation of its biosimilar Hyrimoz injection. The adalimumab citrate-free HCF 100 mg/mL is approved to treat seven indications covered by the reference medicine, Humira, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis and plaque psoriasis. Sandoz intends to launch the Hyrimoz citrate-free HCF in the U.S. on July 1, the company stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVS:
- Novartis terminates collaboration and license pact with Sangamo
- Novartis’ Tafinlar + Mekinist approved by FDA for pediatric patients
- Novartis’ Sandoz signs MOU to build new biologics production plant in Slovenia
- Voyager announces Novartis exercised option to license novel capsids for $25M
- Novartis treatment of multiple myeloma granted orphan designation